AETHLON MEDICAL INCAEMDEarnings & Financial Report
Aethlon Medical Inc. is a clinical-stage medical technology firm that develops targeted therapeutic devices to address life-threatening health conditions. Its lead product, the Hemopurifier, is designed to remove harmful viruses, cancer-derived exosomes, and other pathogens from the bloodstream. The company primarily operates in the infectious disease and oncology healthcare segments, with main market presence in North America.
Revenue
$95.1K
Gross Profit
N/A
Operating Profit
$-2.9M
Net Profit
$-2.8M
Gross Margin
N/A
Operating Margin
-3050.2%
Net Margin
-2950.2%
YoY Growth
N/A
EPS
$-16.11
AETHLON MEDICAL INC Q2 FY2025 Financial Summary
AETHLON MEDICAL INC reported revenue of $95.1K for Q2 FY2025, with a net profit of $-2.8M (up 7.5% YoY) (-2950.2% margin).
Key Financial Metrics
| Total Revenue | $95.1K |
|---|---|
| Net Profit | $-2.8M |
| Gross Margin | N/A |
| Operating Margin | -3050.2% |
| Report Period | Q2 FY2025 |
AETHLON MEDICAL INC Quarterly Revenue & Net Profit History
AETHLON MEDICAL INC results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $60.0K | — | $-1.8M | -2926.4% |
| Q2 FY2025 | $95.1K | — | $-2.8M | -2950.2% |
Income Statement
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Revenue | $95146 | $59964 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Assets | $8.8M | $6.5M |
| Liabilities | $2.8M | $2.2M |
| Equity | $6.0M | $4.3M |
Cash Flow
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Operating CF | $-2.2M | $-2.0M |